DTIL - Jefferies sees 93% upside in Avadel Pharma in premarket analyst action April, 03 2020 07:06 AM Precision BioSciences Inc. Arcus Biosciences (NYSE:RCUS) initiated with Overweight rating and $21 (41% upside) price target at Cantor Fitzgerald.More news on: Avadel Pharmaceuticals plc, Arcus Biosciences, Inc., Integra LifeSciences Holdings Corporation, Healthcare stocks news, Stocks on the move, , Read more ...